<DOC>
	<DOCNO>NCT00018954</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness two treatment regimen patient develop country diffuse non-Hodgkin 's lymphoma acute lymphoblastic leukemia .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Acute Lymphoblastic Leukemia Diffuse Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Provide standard protocol specific therapy relatively easy administer relatively inexpensive conforms modern treatment principle , determine whether therapy administer safely effectively patient acute lymphoblastic lymphoma diffuse non-Hodgkin 's lymphoma live develop country . - Determine rate relapse survival patient treated protocol , relate data disease subtype clinical presentation order obtain database build future stratagem . OUTLINE : This multicenter study . Patients acute lymphoblastic leukemia lymphoblastic lymphoma degree bone marrow involvement assign Protocol MCP-841 . Patients mediastinal localize lymphoblastic lymphoma ( single nodal extranodal site ) without bone marrow involvement , type diffuse non-Hodgkin 's lymphoma without bone marrow involvement assign Protocol MCP-842 . Protocol MCP-841 : - First induction therapy : Patients receive daunorubicin ( DNR ) IV day 8 , 15 , 29 ; vincristine ( VCR ) IV day 1 , 8 , 15 , 22 , 29 ; asparaginase ( ASP ) intramuscularly ( IM ) every day day 2-20 ; oral prednisone ( PRED ) day 1-28 ; methotrexate ( MTX ) intrathecally ( IT ) day 1 , 8 , 15 , 22 . Second induction therapy : Patients receive oral mercaptopurine ( MP ) day 1-7 15-21 ; cyclophosphamide ( CTX ) IV 30 minute day 1 15 ; MTX IT first induction therapy ; cranial irradiation day 4-14 . - Alternative second induction ( cranial irradiation facility unavailable ) : Patients receive MP CTX second induction therapy ; cytarabine ( ARA-C ) IV every 12 hour day 1 , 2 , 15 , 16 , 29 , 30 ; MTX IT day 8 22 . Patients low-risk disease ( WBC great 10,000/mm3 , age 3 6 year , prominent lymphadenopathy ( le 3 cm diameter nodal region ) , normal CSF , mediastinal mass , enlargement liver spleen , cranial nerve palsy ) proceed directly maintenance therapy . All patient consider high risk , repeat first induction therapy proceed consolidation therapy . - Consolidation therapy : Patients receive MP CTX second induction therapy , VCR IV day 1 15 , ARA-C subcutaneously ( SC ) every 12 hour day 1-3 15-17 . - Maintenance therapy : Patients receive VCR IV day 1 ; DNR IV day 1 ; oral PRED day 1-7 ; ASP IM day 1 , 3 , 5 , 7 ; oral MTX weekly oral MP daily day 15-35 , 43-63 , 71-91 . Maintenance therapy continue total 6 course . Protocol MCP-842 : - Patients undergo surgical resection intra-abdominal mass , feasible . Patients low-risk disease ( completely resect tumor single extra-abdominal site involvement ( mediastinum ) , without lymphoblastic lymphoma ) assign treatment group 2 . All patient , include lymphoblastic lymphoma without bone marrow involvement , consider high risk assign treatment group 1 . - Group 1 ( high risk ) : Patients receive one course regimen A comprising CTX IV 15 minute day 1-4 ; VCR IV day 1 , 8 , 15 ; doxorubicin ( DOX ) IV day 1 2 ; ARA-C IV 3 hour every 12 hour day 1 ; ARA-C IT day 4 ; MTX IT day 8 12 . Patients receive one course regimen B comprise ifosfamide IV 30 minute day 1-5 , etoposide IV 1 hour MTX IV day 1-3 , VCR IV day 8 , ARA-C IT day 1 4 , MTX IT regimen A . Patients receive second course regimen A , follow second course regimen B . - Group 2 ( low risk ) : Patients receive one course regimen A , follow one course regimen B , second course regimen A. DOX withheld course regimen A . IT therapy withheld second course regimen A . Patients follow every 2 month 1 year ( Protocol MCP-841 ) 1 , 2 , 3 , 4 , 6 , 8 month ( Protocol MCP-842 ) , every 6 month 5 year , annually thereafter . PROJECTED ACCRUAL : A total 4,000 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>6-Mercaptopurine</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose acute lymphoblastic leukemia ( ALL ) Lymphoblasts comprise 25 % nucleated cell bone marrow aspirate Associated appropriate clinical syndrome OR Histologically proven newly diagnose diffuse nonHodgkin 's lymphoma ( NHL ) Immunologic and/or cytochemical confirmation diagnosis prefer PATIENT CHARACTERISTICS : Age : ALL : Under 25 NHL : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other No prior therapy ALL NHL</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>stage I childhood lymphoblastic lymphoma</keyword>
	<keyword>stage II childhood lymphoblastic lymphoma</keyword>
	<keyword>stage III childhood lymphoblastic lymphoma</keyword>
	<keyword>stage IV childhood lymphoblastic lymphoma</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated childhood acute lymphoblastic leukemia</keyword>
	<keyword>stage I adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage I adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage I childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage I childhood large cell lymphoma</keyword>
	<keyword>stage II childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage II childhood large cell lymphoma</keyword>
	<keyword>stage III childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage III childhood large cell lymphoma</keyword>
	<keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
	<keyword>stage IV childhood large cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage I small lymphocytic lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>contiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
</DOC>